Announcements

01

2022

Update on the Development of Proprietary Antibodies for Early-Stage Lung Cancer Detection Tests and Initial Indications in Detecting Other Cancers

05/07/2022

27/06/2022

Marketing Agreement to Enhance Expansion in the USA

16/06/2022

Posting of Annual Report and Notice of AGM

01/06/2022

Results for the year ended 31 December 2021

30/05/2022

Strategic Alliance to develop and market early lung cancer detection in USA

06/05/2022

Further Research Agreement with the University of York for Cancer Diagnosis and Therapy

11/04/2022

Further positive outcomes from the Arcadia Clinical Trial by SGSC and Excalibur Medicines for Cizzle Biotechnology’s Royalty Bearing interest in AZD1656

07/03/2022

Holdings in Company

18/02/2022

Total Voting Rights

16/02/2022

Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases

14/02/2022

Holdings in Company

04/02/2022

Royalty Strategic Alliance for Early Lung Cancer Detection in China

03/02/2022

Holdings in Company

02/02/2022

Holdings in Company

02/02/2022

Holdings in Company

02/02/2022

Holdings in Company

19/01/2022

02

2021

Holdings in Company

07/12/2021

Strategic Alliance for Early Lung Cancer Detection in China

25/11/2021

Grant of Options

04/11/2021

Companion Diagnostic Supply Agreement with St George Street Capital

22/10/2021

Interim results for the six months ended 30 June 2021

30/09/2021

Agreement with St George Street Capital

20/09/2021

New Research Agreement with the University of York for Cancer Tests

17/09/2021

Encouraging progress on collaboration with St George Street Capital

09/09/2021

Collaboration with FairJourney Biologics to Develop Proprietary Antibodies for Early Lung Cancer Detection Tests

22/07/2021

29/06/2021

29/06/2021

MOU for the Development of a Companion Diagnostic

22/06/2021

Holdings in Company

07/06/2021

2020 Annual Report and Notice of General Meeting

06/06/2021

Bould First Day of Dealings

14/05/2021

Bould Results of AGM and GM

13/05/2021